Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists

Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.

Original languageEnglish (US)
Pages (from-to)675-682
Number of pages8
JournalJournal of child neurology
Issue number6
StatePublished - Jun 1 2011


  • acute disseminated encephalomyelitis
  • multiple sclerosis
  • optic neuritis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists'. Together they form a unique fingerprint.

Cite this